Abstract
Brain metastases (BM) develop during the disease course in 20-65% of lung cancer patients. As neo-angiogenesis is crucial to BM growth, the combination of angiogenesis inhibitors and brain radiotherapy is an active focus of research. Apatinib, a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2, is safe and significantly prolongs survival in chemotherapy-refractory gastric cancer. This prospective study evaluated the safety and efficacy of apatinib combined with concurrent whole brain radiation therapy (WBRT) in lung cancer patients with BM.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
